| 000 | 01848 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250518055933.0 | ||
| 264 | 0 | _c20210111 | |
| 008 | 202101s 0 0 eng d | ||
| 022 | _a1724-6016 | ||
| 024 | 7 |
_a10.1177/1120672119871886 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYoneda, Ai | |
| 245 | 0 | 0 |
_aInitial treatment for polypoidal choroidal vasculopathy: Ranibizumab combined with photodynamic therapy or fixed-dosing aflibercept monotherapy. _h[electronic resource] |
| 260 |
_bEuropean journal of ophthalmology _cNov 2020 |
||
| 300 |
_a1473-1479 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aChoroid _xblood supply |
| 650 | 0 | 4 |
_aChoroid Diseases _xdiagnosis |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFluorescein Angiography |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aFundus Oculi |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIntravitreal Injections |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPhotochemotherapy _xmethods |
| 650 | 0 | 4 |
_aPolyps _xdiagnosis |
| 650 | 0 | 4 |
_aRanibizumab _xadministration & dosage |
| 650 | 0 | 4 |
_aReceptors, Vascular Endothelial Growth Factor _xadministration & dosage |
| 650 | 0 | 4 |
_aRecombinant Fusion Proteins _xadministration & dosage |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTomography, Optical Coherence |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
| 650 | 0 | 4 | _aVisual Acuity |
| 700 | 1 | _aWakiyama, Harumi | |
| 700 | 1 | _aKurihara, Junko | |
| 700 | 1 | _aKitaoka, Takashi | |
| 773 | 0 |
_tEuropean journal of ophthalmology _gvol. 30 _gno. 6 _gp. 1473-1479 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/1120672119871886 _zAvailable from publisher's website |
| 999 |
_c30068621 _d30068621 |
||